# Daiichi Sankyo Europe

**Type:** Funders  
**Canonical URL:** https://scholariq.org/funders/daiichi-sankyo-europe/

## Facts

| Field | Value |
| --- | --- |
| Country | DE |
| Description | company in Munich, Germany |
| OpenAlex ID | https://openalex.org/F4320338262 |
| Works | 11,344 |

## Funder papers

Showing 15 of 20.

- [Intensive Blood Glucose Control and Vascular Outcomes in Patients with Type 2 Diabetes](https://scholariq.org/papers/intensive-blood-glucose-control-and-vascular-outcomes-in-patients-with-type-2/)
- [Angiotensin–Neprilysin Inhibition in Heart Failure with Preserved Ejection Fraction](https://scholariq.org/papers/angiotensin-neprilysin-inhibition-in-heart-failure-with-preserved-ejection/)
- [Efficacy of Dapagliflozin on Renal Function and Outcomes in Patients With Heart Failure With Reduced Ejection Fraction](https://scholariq.org/papers/efficacy-of-dapagliflozin-on-renal-function-and-outcomes-in-patients-with-heart/)
- [Canagliflozin and Cardiovascular and Renal Outcomes in Type 2 Diabetes Mellitus and Chronic Kidney Disease in Primary and Secondary Cardiovascular Prevention Groups](https://scholariq.org/papers/canagliflozin-and-cardiovascular-and-renal-outcomes-in-type-2-diabetes-mellitus/)
- [Safety and Efficacy of Eplerenone in Patients at High Risk for Hyperkalemia and/or Worsening Renal Function](https://scholariq.org/papers/safety-and-efficacy-of-eplerenone-in-patients-at-high-risk-for-hyperkalemia-and/)
- [Long-term kidney outcomes of semaglutide in obesity and cardiovascular disease in the SELECT trial](https://scholariq.org/papers/long-term-kidney-outcomes-of-semaglutide-in-obesity-and-cardiovascular-disease/)
- [Initial Decline (Dip) in Estimated Glomerular Filtration Rate After Initiation of Dapagliflozin in Patients With Heart Failure and Reduced Ejection Fraction: Insights From DAPA-HF](https://scholariq.org/papers/initial-decline-dip-in-estimated-glomerular-filtration-rate-after-initiation-of/)
- [Molecular Biomarkers of Disease Outcomes and Mechanisms of Acquired Resistance to First-Line Osimertinib in Advanced EGFR-Mutant Lung Cancers](https://scholariq.org/papers/molecular-biomarkers-of-disease-outcomes-and-mechanisms-of-acquired-resistance/)
- [Effects of empagliflozin on progression of chronic kidney disease: a prespecified secondary analysis from the empa-kidney trial](https://scholariq.org/papers/effects-of-empagliflozin-on-progression-of-chronic-kidney-disease-a-prespecified/)
- [Effects of canagliflozin on cardiovascular, renal, and safety outcomes in participants with type 2 diabetes and chronic kidney disease according to history of heart failure: Results from the CREDENCE trial](https://scholariq.org/papers/effects-of-canagliflozin-on-cardiovascular-renal-and-safety-outcomes-in/)
- [Vericiguat in patients with chronic heart failure and reduced ejection fraction (VICTOR): a double-blind, placebo-controlled, randomised, phase 3 trial](https://scholariq.org/papers/vericiguat-in-patients-with-chronic-heart-failure-and-reduced-ejection-fraction/)
- [Canagliflozin and Kidney-Related Adverse Events in Type 2 Diabetes and CKD: Findings From the Randomized CREDENCE Trial](https://scholariq.org/papers/canagliflozin-and-kidney-related-adverse-events-in-type-2-diabetes-and-ckd/)
- [Small cell transformation in EGFR-mutated non-small cell lung cancer: DLL3 expression and efficacy of immune checkpoint inhibitors or tyrosine kinase inhibitors combined with chemotherapy](https://scholariq.org/papers/small-cell-transformation-in-egfr-mutated-non-small-cell-lung-cancer-dll3/)
- [Genetic background, recent advances in molecular biology, and development of novel therapy in Alport syndrome](https://scholariq.org/papers/genetic-background-recent-advances-in-molecular-biology-and-development-of-novel/)
- [Impact of Oral Semaglutide on Kidney Outcomes in People With Type 2 Diabetes: Results From the SOUL Randomized Trial](https://scholariq.org/papers/impact-of-oral-semaglutide-on-kidney-outcomes-in-people-with-type-2-diabetes/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.